Jeff Yass’s Bluejay Diagnostics BJDX Stock Holding History

Jeff Yass’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3	Closed	-$28.5K	–	12574
2022 Q4	$28.5K	Buy	+3	New	+$65K	﹤0.01%	11639

Other funds holding BJDX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jeff Yass's BJDX Position: Q1 2023 in Review

Jeff Yass sold out of Bluejay Diagnostics (BJDX) in Q1 2023, closing a stake of 3 shares — an estimated $28.5K sold.

Jeff Yass first reported a position in BJDX in Q4 2022 and held it in 1 quarter. The position peaked at $28.5K in Q4 2022. 2 funds tracked by Wall St. Rank hold BJDX as of Q1 2023.

Jeff Yass reported no remaining Bluejay Diagnostics position as of Q1 2023 after selling out during the quarter.
Jeff Yass sold 3 Bluejay Diagnostics shares in Q1 2023, an estimated $28.5K.
Jeff Yass first reported a position in Bluejay Diagnostics in Q4 2022 and held it in 1 quarter.
Jeff Yass's Bluejay Diagnostics position peaked at $28.5K in Q4 2022.
2 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.